{
    "title": "114_hr292",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Advancing Research for Neurological \nDiseases Act of 2015''.\n\nSEC. 2. NATIONAL NEUROLOGICAL DISEASES SURVEILLANCE SYSTEM.\n\n    Part P of title III of the Public Health Service Act (42 U.S.C. \n280g et seq.) is amended by adding at the end the following:\n\n``SEC. 399V-6 SURVEILLANCE OF NEUROLOGICAL DISEASES.\n\n    ``(a) In General.--The Secretary, acting through the Director of \nthe Centers for Disease Control and Prevention, shall--\n            ``(1) enhance and expand infrastructure and activities to \n        track the epidemiology of neurological diseases, including \n        multiple sclerosis and Parkinson's disease; and\n            ``(2) incorporate information obtained through such \n        activities into a statistically-sound, scientifically-credible, \n        integrated surveillance system, to be known as the National \n        Neurological Diseases Surveillance System.\n    ``(b) Research.--The Secretary shall ensure that the National \nNeurological Diseases Surveillance System is designed in a manner that \nfacilitates further research on neurological diseases.\n    ``(c) Content.--In carrying out subsection (a), the Secretary--\n            ``(1) shall provide for the collection and storage of \n        information on the incidence and prevalence of neurological \n        diseases in the United States;\n            ``(2) to the extent practicable, shall provide for the \n        collection and storage of other available information on \n        neurological diseases, such as information concerning--\n                    ``(A) demographics and other information associated \n                or possibly associated with neurological diseases, such \n                as age, race, ethnicity, sex, geographic location, and \n                family history;\n                    ``(B) risk factors associated or possibly \n                associated with neurological diseases, including \n                genetic and environmental risk factors; and\n                    ``(C) diagnosis and progression markers;\n            ``(3) may provide for the collection and storage of \n        information relevant to analysis on neurological diseases, such \n        as information concerning--\n                    ``(A) the epidemiology of the diseases;\n                    ``(B) the natural history of the diseases;\n                    ``(C) the prevention of the diseases;\n                    ``(D) the detection, management, and treatment \n                approaches for the diseases; and\n                    ``(E) the development of outcomes measures; and\n            ``(4) may address issues identified during the consultation \n        process under subsection (d).\n    ``(d) Consultation.--In carrying out this section, the Secretary \nshall consult with individuals with appropriate expertise, including--\n            ``(1) epidemiologists with experience in disease \n        surveillance or registries;\n            ``(2) representatives of national voluntary health \n        associations that--\n                    ``(A) focus on neurological diseases, including \n                multiple sclerosis and Parkinson's disease; and\n                    ``(B) have demonstrated experience in research, \n                care, or patient services;\n            ``(3) health information technology experts or other \n        information management specialists;\n            ``(4) clinicians with expertise in neurological diseases; \n        and\n            ``(5) research scientists with experience conducting \n        translational research or utilizing surveillance systems for \n        scientific research purposes.\n    ``(e) Grants.--The Secretary may award grants to, or enter into \ncontracts or cooperative agreements with, public or private nonprofit \nentities to carry out activities under this section.\n    ``(f) Coordination With Other Federal Agencies.--Subject to \nsubsection (h), the Secretary shall make information and analysis in \nthe National Neurological Diseases Surveillance System available, as \nappropriate, to Federal departments and agencies, such as the National \nInstitutes of Health, the Food and Drug Administration, the Centers for \nMedicare & Medicaid Services, the Agency for Healthcare Research and \nQuality, the Department of Veterans Affairs, and the Department of \nDefense.\n    ``(g) Public Access.--Subject to subsection (h), the Secretary \nshall make information and analysis in the National Neurological \nDiseases Surveillance System available, as appropriate, to the public, \nincluding researchers.\n    ``(h) Privacy.--The Secretary shall ensure that privacy and \nsecurity protections applicable to the National Neurological Diseases \nSurveillance System are at least as stringent as the privacy and \nsecurity protections under HIPAA privacy and security law (as defined \nin section 3009(a)(2)).\n    ``(i) Report.--Not later than 4 years after the date of the \nenactment of this section, the Secretary shall submit a report to the \nCongress concerning the implementation of this section. Such report \nshall include information on--\n            ``(1) the development and maintenance of the National \n        Neurological Diseases Surveillance System;\n            ``(2) the type of information collected and stored in the \n        System;\n            ``(3) the use and availability of such information, \n        including guidelines for such use; and\n            ``(4) the use and coordination of databases that collect or \n        maintain information on neurological diseases.\n    ``(j) Definition.--In this section, the term `national voluntary \nhealth association' means a national nonprofit organization with \nchapters, other affiliated organizations, or networks in States \nthroughout the United States.\n    ``(k) Authorization of Appropriations.--To carry out this section, \nthere is authorized to be appropriated $5,000,000 for each of fiscal \nyears 2015 through 2019.''."
}